EGFR and neoplasm: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which are classic small molecule inhibitors used in targeted treatments, have been shown to prolong the survival time of patients with tumours harboring EGFR-activating mutations from less than 1 year to approximately 20–30 months [2–5].